Preetesh Jain, MD, PhD, discusses the safety profile of combination ibrutinib and rituximab in patients with mantle cell lymphoma.
Preetesh Jain, MD, PhD, a clinical fellow in medical oncology at The University of Texas MD Anderson Cancer Center, discusses the safety profile of combination ibrutinib (Imbruvica) and rituximab (Rituxan) in patients with mantle cell lymphoma (MCL).
This combination is suitable for all patients, with the exception of those who have a significant cardiac history, or ongoing atrial fibrillation, Jain says. It is critical that these patients are thoroughly screened by cardiologists with a cardiogram evaluation prior to receiving the drug, Jain adds. These parameters need to be clarified before offering this regimen to patients, Jain concludes.